Compare OSCR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | IOVA |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 968.6M |
| IPO Year | 2021 | N/A |
| Metric | OSCR | IOVA |
|---|---|---|
| Price | $16.60 | $2.21 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $15.57 | $10.36 |
| AVG Volume (30 Days) | ★ 12.4M | 9.8M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,288,628,000.00 | $250,425,000.00 |
| Revenue This Year | $33.55 | $60.94 |
| Revenue Next Year | $3.30 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 37.38 | ★ 175.62 |
| 52 Week Low | $11.20 | $1.64 |
| 52 Week High | $23.80 | $8.56 |
| Indicator | OSCR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 46.56 |
| Support Level | $15.53 | $2.18 |
| Resistance Level | $17.17 | $2.32 |
| Average True Range (ATR) | 0.90 | 0.12 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 34.35 | 18.11 |
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.